| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Jun, 2021 | Jun, 2020 |
| Sales | 6,500 | 1,490 | 0 | 6,620 | 1,790 |
| Sales Growth | +336.24% | unch | -100.00% | +269.83% | +24.31% |
| Net Income | -63,730 | -43,980 | -28,640 | -44,160 | -36,140 |
| Net Income Growth | -44.91% | -53.56% | +35.14% | -22.19% | -23.56% |
Aktis Oncology Inc (AKTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aktis Oncology Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis Oncology Inc. is based in BOSTON.
Fiscal Year End Date: 12/31